Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Therapy for High Risk Stage III Melanoma
NCT03554083Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2018
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, cobimetinib, vemurafenib, tiragolumab in melanoma, sponsored by Mayo Clinic. Started Oct 2018; status: completed.
02
Drugs
atezolizumabcobimetinibvemurafenibtiragolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03554083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03554083.